LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.lianbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/3/2024 | $5.00 → $3.00 | Buy → Underperform | BofA Securities |
| 12/22/2023 | $7.00 → $4.00 | Buy → Hold | Jefferies |
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Chen to the company's Board of Directors. "I am pleased to welcome Wei Wei Chen to the LianBio board," said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. "Her deep knowledge of the Chinese market, combined with her ability to manage business growth and transformation, will be extremely beneficial to LianBio as we grow our team and make strides toward advancing our diverse pipeline of potentially transformative medicines for patients
SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its
SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities
• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a live virtual analyst and investor event to review EXPLORER-CN topline data and the China market opportunity for mavacamten on Monday, May 1 at 8:00 a.m. EDT / 8:00 p.m. CST SHANGHAI, China and PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to pati
BofA Securities downgraded LianBio from Buy to Underperform and set a new price target of $3.00 from $5.00 previously
Jefferies downgraded LianBio from Buy to Hold and set a new price target of $4.00 from $7.00 previously
15-12G - LianBio (0001831283) (Filer)
EFFECT - LianBio (0001831283) (Filer)
F-6 POS - LianBio (0001831283) (Subject)
S-8 POS - LianBio (0001831283) (Filer)
S-8 POS - LianBio (0001831283) (Filer)
S-8 POS - LianBio (0001831283) (Filer)
POS AM - LianBio (0001831283) (Filer)
25 - LianBio (0001831283) (Filer)
8-K - LianBio (0001831283) (Filer)
8-K - LianBio (0001831283) (Filer)
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
3 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
4 - LianBio (0001831283) (Issuer)
SC 13D/A - LianBio (0001831283) (Subject)
SC 13D - LianBio (0001831283) (Subject)
SC 13G - LianBio (0001831283) (Subject)
SC 13G/A - LianBio (0001831283) (Subject)
SC 13G/A - LianBio (0001831283) (Subject)
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its
SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities
SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023. In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interim Chief Financial Officer. "We are grateful to Yi for her many contributions to strategic initiatives at LianBio and wish her continued success in her next role," said Konstantin Poukalov, Executiv
SHANGHAI, China and PRINCETON, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yizhe Wang, Ph.D., Chief Executive Officer has resigned from LianBio to pursue other opportunities. In connection with his departure, the LianBio Board of Directors has appointed Adam Stone, Chief Investment Officer of Perceptive Advisors and member of the LianBio Board of Directors as Interim Chief Executive Officer. "Under Yizhe's leadership, LianBio built a comprehensive cross-border platform for drug development, advanced multiple programs into pivotal P
SHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that its Board of Directors (the "Board") unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, LLC to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio's programs (the "Proposal"). After careful review and consideration, the Board unanimously concluded that the Proposal unde
SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentra Biosciences, LLC ("Concentra"), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (the "Proposal") to acquire 100% of the equity of LianBio. According to the Schedule 13D filed on November 30, 2023 with the U.S. Securities and Exchange Commission ("SEC") disclosing the Proposal, Tang Capital1 is currently approximately an 8.6% shareholder of Lian
Entered into agreement with Bristol Myers Squibb for mavacamten in China and other Asian marketsPhase 3 data from EXPLORER-CN trial of mavacamten presented in an oral late-breaking science session at the European Society of Cardiology Congress 2023 with simultaneous publication in JAMA Cardiology Topline data announced from Phase 3 trial of TP-03 in Chinese Demodex blepharitis patientsCash, cash equivalents and marketable securities of $252.2 million as of September 30, 2023Strategic review ongoing SHANGHAI and PRINCETON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major
SHANGHAI, China and PRINCETON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced topline results from the Phase 3 LIBRA clinical trial evaluating TP-03 in Chinese patients with Demodex blepharitis. The co-primary endpoints of the LIBRA trial were mite eradication (mite density of 0 mites per lash) and complete collarette cure (collarette score of 0) at day 43. Results demonstrated statistically significant mite eradication in patients with Demodex blepharitis treated with TP-03 compared to vehicle (p<0.001). A positive, but not statistically
SHANGHAI, China and PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the presentation of efficacy and safety data from a Phase 2a study evaluating infigratinib in Chinese patients with locally advanced or metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) with fibroblast growth factor receptor-2 (FGFR2) gene amplification. The data were presented by Dr. Jiajia Yuan, Peking University Cancer Hospital and Institute, at the 2023 European Society for Medical Oncology (ESMO) Congress in a poster titled, "Ef